Dr. Amanda Redden Hathaway, MD

Dr. Hathaway practices at Athens Gastroenterology Endoscopy Center in Athens, Georgia.

Dr. Hathaway's NPI, 1225322431, was assigned on June 6, 2011. Dr. Hathaway graduated from Medical College of Georgia School of Medicine in 2011. Dr. Hathaway holds Georgia license 93739.

Dr. Hathaway's primary practice is Athens Gastroenterology Endoscopy Center, at 3320 Old Jefferson Road, Building 400, Athens, GA 30607. The practice phone is (706) 613-1625.

Dr. Hathaway's primary practice is Athens Gastroenterology Endoscopy Center in Athens, Georgia. Dr. Hathaway is also affiliated with Piedmont Athens Regional. The medical group on file is University Cancer & Blood Center. Dmand AI also links Dr. Hathaway to 4 more hospitals, 2 medical groups, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hathaway practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hathaway's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hathaway is licensed in Georgia.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, deep vein thrombosis (DVT), lymphoma, neutropenia, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Hathaway treats.

CMS data shows 19,671 Medicare services from Dr. Hathaway across 54 procedure codes in 2024, for 514 Medicare patients. Medicare paid $622,734 for them.

CMS counts 514 Medicare patients who saw Dr. Hathaway in 2024. The largest group is 65 to 74, with 221 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hathaway's median patient age at 68, with 62% women.

In 2024, Dr. Hathaway wrote 1,376 Medicare Part D claims for 229 patients. 82% of them were for generic drugs. CMS names the drug for 1,073 of them, across 36 drugs with 11 or more claims each, at $818,388 in total drug cost. In 2023, CMS named 868 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Hathaway for performance year 2024, reported as part of a group. Dr. Hathaway accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hathaway as offering telehealth.

Dmand AI links 7 papers to Dr. Hathaway, published from 2015 to 2024. 2015 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents. Dr. Hathaway's most frequent co-authors are John Pierre Amadon, MD, Brad Albert Keith, MD and Gabrielle Betty Rocque.

Dmand AI links Dr. Hathaway to 5 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Brain Neoplasms, Breast Neoplasms and Vulvar Neoplasms. Open Payments lists research payments to Dr. Hathaway that name 1 trial.

CMS Open Payments shows 1,059 general payments to Dr. Hathaway from 76 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 69% of the total. Eli Lilly and Company paid the most, $116,186. It also lists 3 research payments totaling $5,337 from 2018 to 2020, naming 1 clinical trial.

Dmand AI lists 9 awards for Dr. Hathaway, most recently Outstanding Clinical Fellow in 2017.

Dr. Hathaway graduated from Medical College of Georgia School of Medicine in 2011.

Dr. Hathaway is in network with 19 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.